Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-01-11
1996-08-13
Peselev, Elli
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
A61K 3170, C07M 1708
Patent
active
055456243
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
This invention is concerned with new antibiotics. In particular, this invention relates to compounds which are derivatives of the macrolide antibiotics rosaramicin, repromicin, 5-mycaminosyltylonolide, desmycosin, lactenocin, O-demethyllactenocin, cirramycin A.sub.1, and 23-deoxymycaminosyltylonolide; to the pharmaceutically-acceptable acid addition salts of such derivatives; to a method of using such derivatives in the treatment of illnesses in animals caused by bacterial and mycoplasmic pathogens; and to pharmaceutical compositions useful therefor. The term "animals" includes mammals, fish and birds.
There are numerous agents known to combat bacterial infectious diseases in animals, but for many specific diseases the current agents of choice leave much to be desired. In some instances the agents may not persist long enough in the host and, therefore, require frequent dosing to maintain therapeutically effective blood and/or tissue levels. For meat producing animals (cattle, poultry, sheep and swine) this will require considerable labor intensive animal handling which is costly to the producer. In other cases, the agent may be poorly tolerated or even toxic to the host at therapeutically effective doses. Agents with increased potency, a longer half-life, an increased therapeutic index and a broader spectrum of antibacterial activity as well as agents with greater oral absorption would improve the scope of animal diseases that could be more effectively treated. Thus, the need for new antibacterial and anti-mycoplasmic agents with improved properties endures.
Diseases of particular concern are: bovine respiratory disease, the principal causative bacterial pathogens of which are Pasteurella haemolytica, P. multocida and Haemophilus somnus; pasteurellosis in swine, goats, sheep and poultry (P. multocida); swine pleuropneumonia (Actinobacillus pleuropneumoniae); swine streptococcus infections (Streptococcus suis); and for all of the above mentioned hosts, infections by Mycoplasma spp.
BACKGROUND ART
Derivatives of tylosin and its related macrolides have been shown to be effective against infections in poultry, cattle and pigs caused by certain gram-positive and gram-negative bacteria: Kirst et al., U.S. Pat. No. 4,920,103; Tao et al., U.S. Pat. No. 4,921,947; Kirst et al., U.K. Patent Application GB 2135670A.
DISCLOSURE OF THE INVENTION
This invention is concerned with new antibiotics which are derivatives of the macrolides repromicin, rosaramicin, 5-mycaminosyltylonolide, desmycosin, lactenocin, O-demethyllactenocin, cirramycin A.sub.1, and 23-deoxymycaminosyltylonolide and to the acid addition salts of such derivatives. These new antibiotics have enhanced potency against bacterial pathogens over the parent compounds and are active against mycoplasmic pathogens.
The compounds of the present invention and their pharmaceutically-acceptable salts are of the formula I or II ##STR1## and the pharmaceutically acceptable salts thereof wherein m is 0 or 1;
Q is selected from the group consisting of H, OH, fluoro, chloro, bromo, iodo, OX.sup.2, SX.sup.2, ##STR2## azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, 3,3-dimethylpiperidin-1-yl, hexahydroazepin-1-yl, octahydroazocin-1-yl, octahydroindol-1-yl, 1,3,3a,4,7,7a-hexahydroisoindol-2-yl, decahydroquinol-1-yl, decahydroisoquinol-2-yl, 1,2,3,4-tetrahydroisoquinol-2-yl, 1,2,3,6-tetrahydropyridin-1-yl, 4-alkylpiperazin-1-yl having 1 to 4 carbons in the alkyl portion, morpholino 2,6-dimethylmorpholin-4-yl, thiomorpholino and ##STR3## where R.sup.3 and R.sup.4 are independently selected from the group consisting of H, alkyl having 1 to 4 carbons, hydroxyalkyl having 2 to 4 carbons, cycloalkyl having 3 to 8 carbons, alkenyl having 3 or 4 carbons, alkoxyalkyl having 1 to 4 carbons in the alkoxy portion and 2 to 4 carbons in the alkyl portion and alkoxyalkoxyalkyl having 1 to 4 carbons in each of the alkoxy portions and 2 to 4 carbons in the alkyl portion; and alkyl having 1 to 4 carbons, optionally substituted cycloalkyl having 4 to 8 carbon atoms, and
REFERENCES:
patent: 3975372 (1976-08-01), Ganguly et al.
patent: 4468511 (1984-08-01), Kirst et al.
patent: 4820694 (1989-04-01), Debono et al.
patent: 4920103 (1990-04-01), Kirst et al.
patent: 4921947 (1990-05-01), Tao et al.
patent: 5032581 (1991-07-01), Lukacs et al.
Chemical Abstracts, vol. 102, 1985, Abstract No. 185436n.
Kirst et al., Journal of Antibiotics, vol. XLII, No. 11, pp. 1673-1683, 1989.
Kirst et al., J. Med. Chem., 1988, 31, pp. 1631-1641.
Debono et al., Journal of Antibiotics, vol. XLII, No. 8, pp. 1253-1267, 1989.
Matsubara et al., Journal of Antibiotics, vol. XXXVI, No. 12, pp. 1713-1721, 1983.
Kirst et al., Journal of Antibiotics, vol. XXXV, No. 12, pp. 1675-1682, 1982.
Koshiyama et al., Journal of Antibiotics, vol. XXII, No. 2, pp. 61-64, 1968 .
Hecker Scott J.
Jefson Martin R.
McFarland James W.
Benson Gregg C.
Conway John D.
Peselev Elli
Pfizer Inc.
Richardson P. C.
LandOfFree
Derivatives of 16-membered ring antibiotic macrolides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Derivatives of 16-membered ring antibiotic macrolides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of 16-membered ring antibiotic macrolides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1047977